Reuters: Regulatory News: FDA rejects Allergan migraine drug on manufacturing issues

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA rejects Allergan migraine drug on manufacturing issues Apr 16th 2013, 13:26 April 16 | Tue Apr 16, 2013 9:26am EDT April 16 (Reuters) - U.S. health regulators rejected Allergan Inc's inhaled migraine drug, citing issues related to the company's canister filling unit. The company, whose injectible wrinkle-filler Botox was approved for headaches in October 2010, said the main issues cited in the complete response letter were already identified by the regulator in prior discussions with Allergan. Allergan estimates the next regulatory action on the migraine drug, Levadex, to occur by the end of the fourth quarter of 2013. The drug is an inhaled version of an existing drug, dihydroergotamine, which is typically administered by injection or nasal spray at a headache center or hospital.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions